Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Adaptive Optics Retinal Imaging

The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.

Participants needed: 150
Trial details
Age: 21+Biological sex: AllType: InterventionalSponsor: Food and Drug Administration (FDA)Updated: May 8, 2026Locations: 1
Eligibility criteria

Are 21 years of age or older. [+3]

Are under 21 years of age. [+9]

Read more
Status: Recruiting

Adaptive Optics Imaging of Outer Retinal Diseases

The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.

Participants needed: 100
Trial details
Age: 21+Biological sex: AllType: ObservationalSponsor: Food and Drug Administration (FDA)Updated: May 8, 2026Locations: 2
Eligibility criteria

Are 21 years of age or older, [+3]

Have a condition which prevents adequate images from being obtained (e.g. unstab... [+4]

Read more
Status: Recruiting

Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Perception and Driving Performance in Healthy Adults

With the increasing prevalence and use of cannabis products by the public, there exists a need to better understand the safety impact of cannabis use, particularly when it comes to subjective perceptions of drug effect and driving impairment. This study aims to evaluate the dose-dependent effects of oral Δ9-THC alone and in combination with alcohol (0.08% BAC \[Blood Alcohol Concentration\]) on driving performance and subjective feeling in healthy adults. The results of this study will address current knowledge gaps on the effects of oral Δ9-THC on driving impairment across a clinically relevant dose range.

Participants needed: 48
Trial details
Phase: Phase 1Age: 21-55Biological sex: AllType: InterventionalSponsor: Food and Drug Administration (FDA)Updated: Jan 16, 2026Locations: 2
Eligibility criteria

Subject signs an IRB approved written informed consent and privacy language as p... [+12]

A history of cannabis use disorder or use of any psychoactive drug in the last m... [+26]

Read more